The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan

#	Paper	IF	Citations
174	Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. **2001**, 345, 398-407		103
173	Does plasma HIV RNA predict outcome in a cohort of treated HIV-infected individuals followed over 3 years?. **2001**, 22, 271-8		3
172	Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs. *Aids*, **2001**, 15, 1471-5	3.5	39
171	Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. *Aids*, **2001**, 15, 735-46	3.5	135
170	[Characterization of resistance in HIV. Comparison of geno- and phenotypic resistance to HIV-1 protease inhibitors]. **2001**, 30, 228-32		
169	HIV chemotherapy. **2001**, 410, 995-1001		431
168	ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1. **2001**, 22, 142-59		28
167	Initial virological and immunologic response to highly active antiretroviral therapy predicts long-term clinical outcome. *Clinical Infectious Diseases*, **2001**, 33, 466-72	11.6	43
166	Prevention of hepatitis B infections: vaccination and its limitations. **2001**, 56, 209-19		13
165	Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 3393-402	5.9	7
164	Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. *Clinical Infectious Diseases*, **2001**, 32, 774-82	11.6	90
163	The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. **2002**, 18, 685-93		170
162	Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. **2002**, 99, 8271-6		257
161	Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients. **2002**, 3, 36-44		18
160	Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. *Aids*, **2002**, 16, 1039-44	3.5	86
159	Evaluation of drug resistance in HIV infection. **2002**, 58, 157-202		2
158	Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. **2002**, 31, 128-36		61

139	An algorithm-based genotypic resistance score is associated with clinical outcome in HIV-1-infected adults on antiretroviral therapy. **2004**, 5, 400-6	17
138	Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH (octubre 2004). **2004**, 22, 564-642	1
137	HIV drug resistance. **2004**, 350, 1023-35	574
136	HIV Drug Susceptibility Testing. **2004**, 883-904	
135	PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. **2004**, 4, 337-48	509
134	Drug resistance in non-subtype B HIV-1. **2004**, 29, 152-9	76
133	Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen). **2004**, 37, 1587-98	14
132	Structured treatment interruption in HIV-infected patients failing on multidrug therapy: is there a future for this strategy?. *Aids*, **2005**, 19, 1691-4	3.5	4
131	Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. **2005**, 15, 843-9	40
130	Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir. *Journal of Medical Virology*, **2005**, 76, 447-51	19.7	5
129	Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). *Journal of Medical Virology*, **2005**, 77, 345-50	19.7	24
128	Approach to the treatment-experienced patient. **2005**, 2, 83-9	6
127	Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. **2005**, 62, 809-15	28
126	A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. *Clinical Infectious Diseases*, **2005**, 40, 1828-36	11.6	43
125	Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 1720-6	5.9	49
124	Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. **2005**, 21, 13-6	9
123	HIV type 1 genotypic variation in an antiretroviral treatment-naive population in southern India. **2005**, 21, 301-5	57
122	Computational methods for the design of effective therapies against drug resistant HIV strains. **2005**, 21, 3943-50	82

121	Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. **2006**, 22, 375-85		70
120	[Resistance genotyping in patients with therapeutic failure]. **2006**, 24, 219-21		
119	Primary resistance of human immunodeficiency virus type 1 in a reference center in Recife, Pernambuco, Brazil. **2006**, 101, 845-9		25
118	Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. **2006**, 25, 809-14		20
117	Bioinformatics-assisted anti-HIV therapy. **2006**, 4, 790-7		71
116	Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia. **2006**, 195, 107-12		10
115	Algorithms for the interpretation of HIV-1 genotypic drug resistance information. **2006**, 71, 335-42		45
114	Effects of drug resistance on viral load in patients failing antiretroviral therapy. *Journal of Medical Virology*, **2006**, 78, 608-13	19.7	28
113	A cohort study of enfuvirtide immunological and virological efficacy in clinical practice. *Journal of Medical Virology*, **2006**, 78, 1312-7	19.7	8
112	Defining clinically relevant HIV drug resistance--from drug development to clinical reality. *Aids*, **2006**, 20, 929-31	3.5	1
111	Bioinformatics approach to predicting HIV drug resistance. **2006**, 6, 207-15		12
110	Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective. **2006**, 22, 1110-2		2
109	Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia. **2006**, 22, 121-4		23
108	Detection and quantification of minority HIV isolates harbouring the D30N mutation by real-time PCR amplification. *Journal of Antimicrobial Chemotherapy*, **2007**, 60, 881-4	5.1	7
107	Genotypic resistance of archived and circulating viral strains in the blood of treated HIV-infected individuals. **2007**, 44, 518-24		28
106	Long-term immunologic and virologic responses in patients with highly resistant HIV infection who are treated with an incompletely suppressive antiretroviral regimen. *Clinical Infectious Diseases*, **2007**, 45, 1085-92	11.6	5
105	Effects of pharmacistsⱣinterventions on patient outcomes in an HIV primary care clinic. **2007**, 64, 2574-8		47
104	The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. *Clinical Infectious Diseases*, **2007**, 44, 1475-83	11.6	14

103	Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. *Aids*, **2007**, 21, F11-8	3.5	94
102	Human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns among treatment-naive patients in different stages of infection in Rio de Janeiro, Brazil. *Journal of Medical Virology*, **2007**, 79, 1033-9	19.7	11
101	Optimal drug treatment regimens for HIV depend on adherence. **2007**, 246, 499-509		35
100	Pathogen profiling for disease management and surveillance. **2007**, 5, 464-70		65
99	Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China. *Archives of Virology*, **2007**, 152, 1799-805	2.6	19
98	Study of HIV-1 drug resistance in patients receiving free antiretroviral therapy in China. **2007**, 22, 233-240		2
97	Resampling-based multiple testing methods with covariate adjustment: application to investigation of antiretroviral drug susceptibility. **2008**, 64, 329-36		1
96	[Resistance to integrase inhibitors]. **2008**, 26 Suppl 12, 40-6		8
95	Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. **2008**, 9, 11-25		8
94	Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure. **2008**, 197, 1408-18		34
93	The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART. *Journal of Medical Virology*, **2009**, 81, 1323-35	19.7	9
92	[Genotypic resistance in HIV-1-infected patients with persistent low-level viremia]. **2009**, 27, 75-80		4
91	A comparison of interpretation by three different HIV type 1 genotypic drug resistance algorithms using sequences from non-clade B HIV type 1 strains. **2009**, 25, 315-8		3
90	Detection of drug resistance-associated and background mutations in human immunodeficiency virus type 1 CRF01_AE protease and reverse transcriptase derived from drug treatment-naive patients residing in central Thailand. **2009**, 25, 625-31		8
89	Human Immunodeficiency Virus. **2009**, 737-783		
88	Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina. *Antiviral Therapy*, **2009**, 14, 1175-81	1.6	4
87	Molecular dynamics simulations exploring drug resistance in HIV-1 proteases. **2010**, 55, 2677-2683		6
86	Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. **2010**, 402, 338-46		54

85	Changes in the use of HIV antiretroviral resistance testing in a large cohort of U.S. patients, 1999 to 2006. **2010**, 53, 625-32		8
84	Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype BP strains from former blood donors in central Chinese provinces. **2010**, 26, 1007-13		14
83	Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China. **2010**, 14, 31-41		5
82	Transmitted HIV-1 drug resistance among young men of color who have sex with men: a multicenter cohort analysis. **2011**, 48, 94-9		16
81	The development of an expert system to predict virological response to HIV therapy as part of an online treatment support tool. *Aids*, **2011**, 25, 1855-63	3.5	21
80	Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009. **2011**, 17, 1352-5		6
79	Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. **2011**, 91, 167-76		29
78	Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. **2012**, 50, 1936-42		126
77	What do molecules do when we are not looking? State sequence analysis for stochastic chemical systems. **2012**, 9, 3411-25		1
76	Pretreatment HIV-1 drug resistance is strongly associated with virologic failure in HIV-infected patients receiving partly active antiretroviral regimens. **2012**, 7, 929-32		4
75	Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 2873-8	5.9	52
74	Prevalence of transmitted HIV drug resistance among newly diagnosed antiretroviral therapy-naive pregnant women in Lilongwe and Blantyre, Malawi. *Clinical Infectious Diseases*, **2012**, 54 Suppl 4, S324-7	11.6	5
73	Virological response and HIV drug resistance 12 months after antiretroviral therapy initiation at 2 clinics in Nigeria. *Clinical Infectious Diseases*, **2012**, 54 Suppl 4, S375-80	11.6	27
72	Optimizing background therapy in treatment-experienced HIV-1 patients by rules-based algorithms and bioinformatics. *Future Virology*, **2012**, 7, 749-757	2.4	2
71	Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B. *Current Hepatitis Reports*, **2012**, 11, 55-64		1
70	The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients. *PLoS Computational Biology*, **2013**, 9, e1003203	5	17
69	Transmitted HIV drug resistance in treatment-naive Romanian patients. *Journal of Medical Virology*, **2013**, 85, 1139-47	19.7	13
68	HIV-1 drug resistance in treatment-naive chronically infected patients in Jamaica. *Antiviral Therapy*, **2013**, 18, 941-4	1.6	8

67	The case for addressing primary resistance mutations to non-nucleoside reverse transcriptase inhibitors to treat children born from mothers living with HIV in sub-Saharan Africa. *Journal of the International AIDS Society*, **2014**, 17, 18526	5.4	8
66	Molecular docking studies of chromone derivatives against wild type and mutant strains of HIV-1 protease. *Medicinal Chemistry Research*, **2014**, 23, 4198-4208	2.2	4
65	Emerging trends of HIV drug resistance in Chinese HIV-infected patients receiving first-line highly active antiretroviral therapy: a systematic review and meta-analysis. *Clinical Infectious Diseases*, **2014**, 59, 1495-502	11.6	30
64	The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy. *AIDS Research and Therapy*, **2014**, 11, 36	3	12
63	Low Virologic Failure and Drug Resistance among HIV-Infected Patients Receiving Hospital-Based ART While Care and Outreach through Community in Guangxi, China. *Frontiers in Public Health*, **2015**, 3, 244	6	11
62	Antiretroviral Therapy for Human Immunodeficiency Virus Infection. **2015**, 1622-1641.e6		2
61	Comparison of susceptibility of HIV-1 variants to antiretroviral drugs by genotypic and recombinant virus phenotypic analyses. *International Journal of Infectious Diseases*, **2015**, 37, 86-92	10.5	3
60	HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 6824-33	5.9	41
59	Effectiveness of first-line antiretroviral therapy in HIV/AIDS patients: A 5-year longitudinal evaluation in Fujian Province, Southeast China. *Archives of Virology*, **2015**, 160, 2693-701	2.6	4
58	Human Immunodeficiency Virus. **2016**, 795-840		
57	An update to the HIV-TRePS system: the development and evaluation of new global and local computational models to predict HIV treatment outcomes, with or without a genotype. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 2928-37	5.1	6
56	Promises and pitfalls of Illumina sequencing for HIV resistance genotyping. *Virus Research*, **2017**, 239, 97-105	6.4	18
55	2018 update to the HIV-TRePS system: the development of new computational models to predict HIV treatment outcomes, with or without a genotype, with enhanced usability for low-income settings. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 2186-2196	5.1	4
54	From Sequence Data to Patient Result: A Solution for HIV Drug Resistance Genotyping With Exatype, End to End Software for Pol-HIV-1 Sanger Based Sequence Analysis and Patient HIV Drug Resistance Result Generation. *Journal of the International Association of Providers of AIDS Care*, **2020**, 19, 2325958220962687	1.7	1
53	Polymorphisms and drug resistance analysis of HIV-1 isolates from patients on first line antiretroviral therapy (ART) in South-eastern Nigeria. *PLoS ONE*, **2020**, 15, e0231031	3.7	1
52	2021 update to HIV-TRePS: a highly flexible and accurate system for the prediction of treatment response from incomplete baseline information in different healthcare settings. *Journal of Antimicrobial Chemotherapy*, **2021**, 76, 1898-1906	5.1	
51	Arevir: A Secure Platform for Designing Personalized Antiretroviral Therapies Against HIV. *Lecture Notes in Computer Science*, **2006**, 185-194	0.9	9
50	Clinical Significance and Biological Basis of HIV Drug Resistance. **2008**, 231-261		1

49	Ribozymes as Gene Therapeutic Agents for HIV/AIDS. **2002**, 39-51		1
48	Adaptation of advanced clinical virology assays from HIV-1 to SARS-CoV-2. *Current Opinion in HIV and AIDS*, **2021**, 16, 3-10	4.2	1
47	Susceptibility Test Methods: Viruses. 1913-1931		1
46	Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages. *PLoS ONE*, **2011**, 6, e17190	3.7	30
45	HIV drug resistance and its impact on antiretroviral therapy in Chinese HIV-infected patients. *PLoS ONE*, **2013**, 8, e54917	3.7	34
44	Computational models as predictors of HIV treatment outcomes for the Phidisa cohort in South Africa. *Southern African Journal of HIV Medicine*, **2016**, 17, 450	1.4	4
43	Snake venom preparation for drug-resistant human immunodeficiency virus. *Annals of Saudi Medicine*, **2008**, 28, 292-3	1.6	7
42	HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria. *Aids*, **2022**, 36, 137-146	3.5	2
41	Human Immunodeficiency Virus. **2002**, 95-125		
40	Molecular Diagnostics. **2002**, 37-63		
39	Human Immunodeficiency Virus. **2009**, 47-68		
38	Clinical Manifestations of HIV Infections. **2011**, 301-317		
37	Susceptibility Test Methods: Viruses *. **2011**, 1729-1743		
36	Docking and Molecular Dynamics Calculations of Some Previously Studied and newly Designed Ligands to Catalytic Core Domain of HIV-1 Integrase and an Investigation to Effects of Conformational Changes of Protein on Docking Results. *Journal of the Turkish Chemical Society, Section A: Chemistry*, **2017**,	0.5	4
35	From sequence data to patient result: a solution for HIV drug resistance genotyping with Exatype, end to end software for Pol-HIV-1 Sequence analysis and patient HIV drug resistance result generation.		
34	HIV Drug Susceptibility and Treatment Response to Mega-Haart Regimen in Patients from the Frankfurt HIV Cohort. *Antiviral Therapy*, **2000**, 5, 49-55	1.6	33
33	Principles of HIV Resistance Testing and Overview of Assay Performance Characteristics. *Antiviral Therapy*, **2000**, 5, 27-31	1.6	10
32	Limits of Resistance Testing. *Antiviral Therapy*, **2000**, 5, 71-76	1.6	7

31	Antiretroviral Resistance Testing Comes of Age. *Antiviral Therapy*, **2000**, 5, 23-26	1.6	11
30	Current Insights into Reverse Transcriptase Inhibitor-Associated Resistance. *Antiviral Therapy*, **2001**, 6, 11-19	1.6	4
29	Mutational Patterns in the HIV Genome and Cross-Resistance following Nucleoside and Nucleotide Analogue Drug Exposure. *Antiviral Therapy*, **2001**, 6, 25-44	1.6	51
28	HIV-1 Reverse Transcriptase Mutations Found in a Drug-Experienced Patient Confer Reduced Susceptibility to Multiple Nucleoside Reverse Transcriptase Inhibitors. *Antiviral Therapy*, **2002**, 6, 231-238	1.6	
27	A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients. *Antiviral Therapy*, **2002**, 7, 123-129	1.6	83
26	Association of Antiretroviral Resistance Genotypes with Response to Therapy [Comparison of Three Models. *Antiviral Therapy*, **2002**, 7, 151-157	1.6	2
25	Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy. *Antiviral Therapy*, **2002**, 7, 165-174	1.6	53
24	Analysis of Virological Efficacy in Trials of Antiretroviral Regimens: Drawbacks of Not Including Viral Load Measurements after Premature Discontinuation of Therapy. *Antiviral Therapy*, **2002**, 7, 271-281	1.6	9
23	Drug Resistance Genotypes Predict Response to Amprenavir-Containing Regimens in Highly Drug-Experienced HIV-1-Infected Patients. *Antiviral Therapy*, **2003**, 8, 301-308	1.6	
22	Impact of Genotypic Resistance Testing on Selection of Salvage Regimen in Clinical Practice. *Antiviral Therapy*, **2003**, 8, 443-454	1.6	18
21	Modest Decreases in Nnrti Susceptibility Do Not Influence Virological Outcome in Patients Receiving Initial Nnrti-Containing Triple Therapy. *Antiviral Therapy*, **2003**, 8, 395-402	1.6	3
20	Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance. *Antiviral Therapy*, **2003**, 8, 489-506	1.6	43
19	A Randomized Trial of Nelfinavir and Abacavir in Combination with Efavirenz and Adefovir Dipivoxil in HIV-1-Infected Persons with Virological Failure Receiving Indinavir. *Antiviral Therapy*, **2003**, 8, 507-518	1.6	6
18	The Effect of Number of Mutations and of Drug-Class Sparing on Virological Response to Salvage Genotype-Guided Antiretroviral Therapy. *Antiviral Therapy*, **2003**, 8, 611-616	1.6	7
17	Simple Linear Model Provides Highly Accurate Genotypic Predictions of HIV-1 Drug Resistance. *Antiviral Therapy*, **2004**, 9, 343-352	1.6	26
16	Variability in the Interpretation of Transmitted Genotypic HIV-1 Drug Resistance and Prediction of Virological Outcomes of the Initial Haart by Distinct Systems. *Antiviral Therapy*, **2004**, 9, 743-752	1.6	12
15	Baseline Resistance and Virological Outcome in Patients with Virological Failure who Start a Regimen Containing Abacavir: Eurosida Study. *Antiviral Therapy*, **2004**, 9, 787-800	1.6	2
14	Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing. *Antiviral Therapy*, **2004**, 9, 829-848	1.6	73

13	Enfuvirtide in HIV-1-Infected Individuals Changing Therapy to A Nucleoside Reverse Transcriptase Inhibitor Sparing Regimen: The Alliance Study. *Antiviral Therapy*, **2006**, 11, 409-419	1.6	6
12	Role of the Inhibitory Quotient in HIV Therapy. *Antiviral Therapy*, **2005**, 10, 879-892	1.6	22
11	HIV-1 Subtypes and Response to Combination Antiretroviral Therapy in Europe. *Antiviral Therapy*, **2006**, 11, 707-716	1.6	36
10	Threshold survey evaluating transmitted HIV drug resistance among public antenatal clinic clients in Addis Ababa, Ethiopia. *Antiviral Therapy*, **2008**, 13, 89-94	1.6	27
9	Declining Prevalence of HIV-1 Drug Resistance in Treatment-Failing Patients: A Clinical Cohort Study. *Antiviral Therapy*, **2007**, 12, 835-839	1.6	20
8	Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype. *Antiviral Therapy*, **2009**, 14, 273-283	1.6	4
7	Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy. *Antiviral Therapy*, **2009**, 14, 359-369	1.6	12
6	Historical resistance profile helps to predict salvage failure. *Antiviral Therapy*, **2009**, 14, 285-291	1.6	16
5	Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up. **2001**, 6, 21-39		13
4	Evolution of Antiretroviral Phenotypic and Genotypic Drug Resistance in Antiretroviral-Naive HIV-1-Infected Children Treated with Abacavir/Lamivudine, Zidovudine/Lamivudine or Abacavir/Zidovudine, with or without Nelfinavir (The Penta 5 Trial). *Antiviral Therapy*, **2002**, 7, 293-303	1.6	15
3	Low Genetic Barrier to Large Increases in HIV-1 Cross-Resistance to Protease Inhibitors during Salvage Therapy. *Antiviral Therapy*, **2006**, 11, 143-154	1.6	5
2	Genotypic Resistance Testing of HIV-1 DNA in Peripheral Blood Mononuclear Cells.		0
1	Emergence of Multidrug Resistance Microbes: Bacteria, Fungi, and Viruses. **2023**, 28-67		0